38074--6/14/2006--FOREST_LABORATORIES_INC

related topics
{product, candidate, development}
{product, liability, claim}
{customer, product, revenue}
{property, intellectual, protect}
{tax, income, asset}
{financial, litigation, operation}
{regulation, government, change}
We are Substantially Dependent on Sales of Our Two Principal Products. Pharmaceutical Research is Expensive and Uncertain. Regulatory Compliance Issues Could Materially Affect Our Operations. Our Business Depends on Intellectual Property Protection. Our Business Model Currently Depends on the Successful In-Licensing of New Product Opportunities. Pharmaceutical Cost-Containment Initiatives May Negatively Affect Our Net Income. We face Substantial Competition from Other Pharmaceutical Manufacturers and Generic Product Distributors. Our Business, and in Particular the Treatment of CNS Disorders, Presents Risk of Product Liability Claims. The Effective Rate of Taxation upon Our Results of Operations is Dependent on Multi-National Tax Considerations. Our Business Could be Negatively Affected By the Performance of Our Collaboration Partners. Many of our Principal Products and Active Pharmaceutical Ingredients are Only Available From a Single Manufacturing Source

Full 10-K form ▸

related documents
38074--5/30/2008--FOREST_LABORATORIES_INC
1062822--3/12/2007--LEXICON_GENETICS_INC/TX
14272--2/22/2008--BRISTOL_MYERS_SQUIBB_CO
1000694--3/6/2006--NOVAVAX_INC
810509--3/31/2008--NEOPROBE_CORP
926763--3/16/2007--ASV_INC_/MN/
858803--12/18/2006--AVANIR_PHARMACEUTICALS
914475--2/7/2006--NEUROCRINE_BIOSCIENCES_INC
897075--3/17/2008--REPROS_THERAPEUTICS_INC.
14272--2/20/2009--BRISTOL_MYERS_SQUIBB_CO
926763--3/16/2006--ASV_INC_/MN/
1123361--3/6/2007--VIASYS_HEALTHCARE_INC
1123361--3/14/2006--VIASYS_HEALTHCARE_INC
943736--3/31/2006--MED-DESIGN_CORP
310158--2/28/2007--SCHERING_PLOUGH_CORP
310158--2/28/2006--SCHERING_PLOUGH_CORP
858803--12/17/2008--AVANIR_PHARMACEUTICALS
897075--3/16/2009--REPROS_THERAPEUTICS_INC.
64978--2/28/2008--MERCK_&_CO_INC
849636--3/16/2006--CORTEX_PHARMACEUTICALS_INC/DE/
858803--12/21/2007--AVANIR_PHARMACEUTICALS
1020214--2/26/2007--CERUS_CORP
918112--11/6/2006--NEUROBIOLOGICAL_TECHNOLOGIES_INC_/CA/
71478--3/15/2006--LIPID_SCIENCES_INC/
817785--3/28/2006--IMMUNE_RESPONSE_CORP
881890--6/14/2010--ABAXIS_INC
1063665--9/23/2010--CORGENIX_MEDICAL_CORP/CO
64978--2/27/2009--MERCK_&_CO_INC
816284--2/17/2009--CELGENE_CORP_/DE/
824068--3/12/2010--ATS_MEDICAL_INC